S451
Clinical - Gynaecological
ESTRO 2026
DM only, and DM+LRF. OSAF defined as the time from failure event to death, calculated only for patients experienced failure. Results: The RW cohort showed a median age of 55 years, 74% squamous cell carcinoma, and 56%/14% moderate/high grade tumors. Compared to EMBRACE II, the RW cohort had a significantly higher number of stage III–IVA
(68vs83%,p=0.007) and positive pelvic/paraaortic lymph node
(35/28vs38/5%,p=0.001). Treatment was inferior in terms of Cisplatin adherence (71.4vs97%,, p=0.002), longer overall treatment time (mean 55vs45 days,p<0.001), 1st brachytherapy HR-CTV volume(43.6vs30.4 cc, p=.019), and the use of MRI with applicator-in-place (74vs100%,p<0.001). However, modern techniques were well- adopted in RW with EFRT field (39vs11%,p=0.003), hybrid interstitial brachytherapy (87vs82%, p=0.5) and D90 HR- CTV (mean 86vs89 Gy10, p=0.32). Despite the differences, no statistically significant difference in disease control or survival was observed: 2-year LC (92%/86%), LRC (84%/74%), DMC (78%/77%), EFS (64%/65%), and OS (82%/77%) with median follow-up time of 25/30 months in Figure1.
Failure patterns were not different, as shown in Figure1. A significant survival drop was observed for patients with any failure type, with median survival (MS) from start of treatment of 26–36 months compared to not reached in the LRF-only arm (p<0.001), as
Made with FlippingBook - Share PDF online